ProstaLund AB - Year-end report 2024
“With several ongoing contract discussions for CoreTherm® Eagle, we are positive about the interest in our treatment and the upcoming international launch”
Fourth quarter
October 1 - December 31
- Net sales amounted to SEK 3,9 million (6,4)
- Operating result amounted to SEK -6,2 million (-3,5)
- Profit after tax amounted to SEK -6,2 million (-3,5)
- Earnings per share before and after dilution amounted to SEK -2,43 (-1,82)
- Cash flow from operating activities amounted to SEK -6,5 million (-5,6)
January 1 - December 31
- Net sales amounted to SEK 13,7 million (22,1)
- Operating result amounted to SEK -22,5 million (-16,9)
- Profit after tax amounted to SEK -22,6 million (-17,0)
- Earnings per share before and after dilution amounted to SEK -6,94 (-9,94)
- Cash flow from operating activities amounted to SEK -22,6 million (-23,7)
- Cash and cash equivalents amounted to SEK 7,8 million (15,0)
Significant events during the quarter
- First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate.
- Short-term results and long-term durability after CoreTherm® treatments presented at the Emirates International Urological Conference in Dubai, UAE.
- Notice of Extraordinary General Meeting regarding a resolution on reverse share split.
- The first ten CoreTherm® Eagle machines have been manufactured.
- ProstaLund announces outcome of warrants series TO 3, with a subscription rate of 94,4%, the company received approximately SEK 3,7 million before issue costs.
- Further study published confirming the good effect of transurethral intraprostatic anaesthesia (TUIA) via our Schelin Catheter® in the treatment of benign prostatic hyperplasia.
- Nomination Committee appointed in ProstLund AB (publ) for the Annual General Meeting 2025.
- Determination of record date for reverse share split in ProstaLund AB.
Significant events after the quarter
- Older men treated with CoreTherm® for benign prostate enlargement have a lower risk of a prostate cancer diagnosis later in life compared to men treated with TURP according to a new Swedish registry study.
- New study confirms the strong efficacy of CoreTherm® in patients with large prostates.
Key figures
| (SEK MILLION) | OCT-DEC 2024 | OCT-DEC 2023 | JAN-DEC 2024 | JAN-DEC 2023 |
| Net sales | 3,9 | 6,4 | 13,7 | 22,1 |
| Gross Margin, (%) | 54,9 | 73,5 | 64,6 | 70,1 |
| Operating profit/loss, EBIT | -6,2 | -3,5 | -22,5 | -16,9 |
| Cash flow from operating activites | -6,5 | -5,6 | -23,0 | -23,7 |
| Cash and cash equivalents | 7,8 | 15,0 | 7,8 | 15,0 |
| Average number of employees | 9 | 5 | 8 | 7 |